title: Recombinant urate oxidase (Rasburicase) for the treatment of hyperuricemia in pediatric patients with hematologic malignancies: Results of a compassionate prospective multicenter study in Korea.
abstract: BACKGROUND
  Hyperuricemia accompanying tumor lysis syndrome is a serious complication in neoplasia with rapid proliferation and destruction. To confirm the efficacy of recombinant urate oxidase (rasburicase) and its safety profile, a phase IV compassionate use prospective study was performed in Korean pediatric patients with hematologic malignancies.
  
  
  METHODS
  Rasburicase was administered at 0.2 mg/kg/day once daily for 3-5 days (twice daily allowed during the first 72 hr) by intravenous route for hyperuricemia (uric acid > 7.5 mg/dl). The study period was 5 weeks and consisted of a baseline assessment within 48 hr before the administration of rasburicase, 3-5 days of assessment during treatment and a follow-up assessment at 4 weeks after its final administration.
  
  
  RESULTS
  The uric acid endpoint (< or =7.0 mg/dl) was reached in 97.3% (36/37) of the patients and uric acid levels were significantly reduced in all patients (P < 0.001). Drug related toxicities were mild and reversible without any grade 4 or serious adverse event associated with rasburicase.
  
  
  CONCLUSIONS
  This study confirms that rasburicase is a safe and effective agent for the treatment of hyperuricemia associated with hematologic malignancies in pediatric patients.
authors.affiliation: Department of Pediatrics, Seoul National University College of Medicine, Seoul, Republic of Korea.
authors.forename: Hee Young
authors.initials: HY
authors.lastname: Shin
authors.forename: Hyoung Jin
authors.initials: HJ
authors.lastname: Kang
authors.forename: Eun Sil
authors.initials: ES
authors.lastname: Park
authors.forename: Hyoung Soo
authors.initials: HS
authors.lastname: Choi
authors.forename: Hyo Seop
authors.initials: HS
authors.lastname: Ahn
authors.forename: Sun Young
authors.initials: SY
authors.lastname: Kim
authors.forename: Nak Gyun
authors.initials: NG
authors.lastname: Chung
authors.forename: Hack Ki
authors.initials: HK
authors.lastname: Kim
authors.forename: So Youn
authors.initials: SY
authors.lastname: Kim
authors.forename: Hoon
authors.initials: H
authors.lastname: Kook
authors.forename: Tai Ju
authors.initials: TJ
authors.lastname: Hwang
authors.forename: Kwang Chul
authors.initials: KC
authors.lastname: Lee
authors.forename: Sun Min
authors.initials: SM
authors.lastname: Lee
authors.forename: Kun Soo
authors.initials: KS
authors.lastname: Lee
authors.forename: Keon Hee
authors.initials: KH
authors.lastname: Yoo
authors.forename: Hong Hoe
authors.initials: HH
authors.lastname: Koo
authors.forename: Mee Jung
authors.initials: MJ
authors.lastname: Lee
authors.forename: Jong Jin
authors.initials: JJ
authors.lastname: Seo
authors.forename: Hyung Nam
authors.initials: HN
authors.lastname: Moon
authors.forename: Thad
authors.initials: T
authors.lastname: Ghim
authors.forename: Chuhl Joo
authors.initials: CJ
authors.lastname: Lyu
authors.forename: Won Sik
authors.initials: WS
authors.lastname: Lee
authors.forename: Yong Mook
authors.initials: YM
authors.lastname: Choi
mesh_terms: D000293:Adolescent; D002648:Child; D002675:Child, Preschool; D004334:Drug Administration Schedule; D005260:Female; D019337:Hematologic Neoplasms / Q000150:complications*; D006801:Humans; D033461:Hyperuricemia / Q000150:complications* / Q000188:drug therapy*; D007223:Infant; D007231:Infant, Newborn; D007723:Korea / Q000453:epidemiology; D008297:Male; D011446:Prospective Studies; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000627:therapeutic use; D006435:Renal Dialysis; D016896:Treatment Outcome; D014503:Urate Oxidase / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D014527:Uric Acid / Q000097:blood
chemical_list: D011994:Recombinant Proteins; C469709:rasburicase; D014527:Uric Acid; D014503:Urate Oxidase